Condition: Familial Hypercholesterolemia · Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia · Apolipoprotein B 100, Familial Defective · Sponsor: Atlantic Health System
Hypercholesterolemia is recognized as the major driver for cardiovascular morbidity and mortality. To help address this in our community, Atlantic Medical Group (AMG) formed a lipid workgroup chaired by Robert D. Fishberg, MD, and Jeffrey N. Feldman, MD. The overarching goal of the lipid workgroup is to enhance the treatment of lipid disorders in those patients with abnormal lipid levels by improving access to resources at the primary care practice level and specialty level. We aim to develop a model for primary and secondary prevention that integrates guidelines for treatment at the practice level. Our primary objective is to identify high-risk patients by utilizing the electronic health record and partnering with patients' primary care providers to provide comprehensive medical management.
This description comes directly from the study's public registry record.
Robert D Fishberg, MD · 973-467-0005 · robert.fishberg@atlantichealth.org
Jeffrey N Feldman, MD · 908-686-9330 · jeffrey.feldman@atlantichealth.org
Always discuss trial participation with your own doctor first.
| Atlantic Medical Group | Clark, New Jersey, United States | Not Yet Recruiting |
| Atlantic Medical Group | Springfield, New Jersey, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06439654